A Helicobacter pylori eradikációjának legújabb szempontjai és a bakteriális rezisztencia jelentosége

Translated title of the contribution: The new aspects of the eradication of Helicobacter pylori and the importance of bacterial resistance

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The first line treatment of Helicobacter pylori infection is a 7-day PPI-based (PPI+clarithromycin+amoxycillin or metronidazole) combined therapy. Success of first eradication attempts in the literature is around 80-90%, while in Hungary 75%. Repeated eradication is needed in 10-25% of cases. The second and third line treatments are successful only in 36% and 20% of cases. Treatment failure is increasing worldwide with the higher rates of bacterial, especially clarithromycin resistance. Patients' noncomplience, pharmacogenetic and pharmacokinetic properties of the applied drugs are important as well. The eradication success rates are unacceptable in populations with higher metronidazole and clarithromycin resistance, that is why there is a need for newer combinations. A possible solution is the application of sequential therapy, or using newer antibiotics (levofloxacine). The importance of new natural substances (lactoferrin, probiotics, plant drugs) must be further investigated.

Original languageHungarian
Pages (from-to)2029-2035
Number of pages7
JournalOrvosi Hetilap
Volume149
Issue number43
DOIs
Publication statusPublished - Oct 26 2008

Fingerprint

Helicobacter pylori
Clarithromycin
Metronidazole
Lactoferrin
Hungary
Pharmacogenetics
Amoxicillin
Probiotics
Helicobacter Infections
Therapeutics
Treatment Failure
Pharmaceutical Preparations
Pharmacokinetics
Anti-Bacterial Agents
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A Helicobacter pylori eradikációjának legújabb szempontjai és a bakteriális rezisztencia jelentosége. / Hagymási, K.; Tulassay, Z.

In: Orvosi Hetilap, Vol. 149, No. 43, 26.10.2008, p. 2029-2035.

Research output: Contribution to journalArticle

@article{4e254df34da34cd5be11d944a356ff17,
title = "A Helicobacter pylori eradik{\'a}ci{\'o}j{\'a}nak leg{\'u}jabb szempontjai {\'e}s a bakteri{\'a}lis rezisztencia jelentos{\'e}ge",
abstract = "The first line treatment of Helicobacter pylori infection is a 7-day PPI-based (PPI+clarithromycin+amoxycillin or metronidazole) combined therapy. Success of first eradication attempts in the literature is around 80-90{\%}, while in Hungary 75{\%}. Repeated eradication is needed in 10-25{\%} of cases. The second and third line treatments are successful only in 36{\%} and 20{\%} of cases. Treatment failure is increasing worldwide with the higher rates of bacterial, especially clarithromycin resistance. Patients' noncomplience, pharmacogenetic and pharmacokinetic properties of the applied drugs are important as well. The eradication success rates are unacceptable in populations with higher metronidazole and clarithromycin resistance, that is why there is a need for newer combinations. A possible solution is the application of sequential therapy, or using newer antibiotics (levofloxacine). The importance of new natural substances (lactoferrin, probiotics, plant drugs) must be further investigated.",
keywords = "Bacterial resistance, Eradication, First and second line treatment, Helicobacter pylori, Sequential therapy, Treatment failure",
author = "K. Hagym{\'a}si and Z. Tulassay",
year = "2008",
month = "10",
day = "26",
doi = "10.1556/OH.2008.28460",
language = "Hungarian",
volume = "149",
pages = "2029--2035",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "43",

}

TY - JOUR

T1 - A Helicobacter pylori eradikációjának legújabb szempontjai és a bakteriális rezisztencia jelentosége

AU - Hagymási, K.

AU - Tulassay, Z.

PY - 2008/10/26

Y1 - 2008/10/26

N2 - The first line treatment of Helicobacter pylori infection is a 7-day PPI-based (PPI+clarithromycin+amoxycillin or metronidazole) combined therapy. Success of first eradication attempts in the literature is around 80-90%, while in Hungary 75%. Repeated eradication is needed in 10-25% of cases. The second and third line treatments are successful only in 36% and 20% of cases. Treatment failure is increasing worldwide with the higher rates of bacterial, especially clarithromycin resistance. Patients' noncomplience, pharmacogenetic and pharmacokinetic properties of the applied drugs are important as well. The eradication success rates are unacceptable in populations with higher metronidazole and clarithromycin resistance, that is why there is a need for newer combinations. A possible solution is the application of sequential therapy, or using newer antibiotics (levofloxacine). The importance of new natural substances (lactoferrin, probiotics, plant drugs) must be further investigated.

AB - The first line treatment of Helicobacter pylori infection is a 7-day PPI-based (PPI+clarithromycin+amoxycillin or metronidazole) combined therapy. Success of first eradication attempts in the literature is around 80-90%, while in Hungary 75%. Repeated eradication is needed in 10-25% of cases. The second and third line treatments are successful only in 36% and 20% of cases. Treatment failure is increasing worldwide with the higher rates of bacterial, especially clarithromycin resistance. Patients' noncomplience, pharmacogenetic and pharmacokinetic properties of the applied drugs are important as well. The eradication success rates are unacceptable in populations with higher metronidazole and clarithromycin resistance, that is why there is a need for newer combinations. A possible solution is the application of sequential therapy, or using newer antibiotics (levofloxacine). The importance of new natural substances (lactoferrin, probiotics, plant drugs) must be further investigated.

KW - Bacterial resistance

KW - Eradication

KW - First and second line treatment

KW - Helicobacter pylori

KW - Sequential therapy

KW - Treatment failure

UR - http://www.scopus.com/inward/record.url?scp=56749150795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56749150795&partnerID=8YFLogxK

U2 - 10.1556/OH.2008.28460

DO - 10.1556/OH.2008.28460

M3 - Article

C2 - 18926961

AN - SCOPUS:56749150795

VL - 149

SP - 2029

EP - 2035

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 43

ER -